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ABSTRACT
A 55-year-old male with a history of two prior
cardiac surgeries presented with decompensated
heart failure due to severe bioprosthetic aortic
valve insufficiency. A third operation was
viewed prohibitively high risk and valve-in--
valve trans-catheter aortic valve replacement
was considered. There were however several
high-risk features and technically challenging
aspects including low coronary ostia height,
poor visualization of the aortic sinuses, and
difficulty in identification of the coplanar view
due to severe aortic insufficiency, and a highly
mobile aortic valve mass. After meticulous
peri-procedural planning, trans-catheter aortic
valve replacement was carried out with a
SAPIEN 3 balloon-expandable valve without
any complication. Strategies undertaken to
navigate the technically challenging aspects of
the case are discussed.
Keywords: Trans-catheter aortic valve
replacement; Freestyle aortic root;
Bioprosthesis; Edwards SAPIEN 3 valve;
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INTRODUCTION
Trans-catheter aortic valve replacement (TAVR)
technology has seen exponential growth in its
utilization and astounding innovation in its
design over the past few years. Steadfast
improvement in its outcomes has quickly
expanded testing this technology from inoper-
able and high-risk surgical patients to interme-
diate-risk and recently low-risk profile patients.
In these studies, only patients with pure and
clear-cut aortic stenosis are randomized and
patients with complicating features such as
mixed aortic valve disease with [3? aortic
insufficiency, intracardiac evidence of mass,
thrombus or vegetation, and low coronary ostia
height are excluded (supplementary appendix
PARTNER trial) [1]. Nonetheless, in real life
practice, there are patients with severe aortic
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valve disease who have these complicating fea-
tures but are also at prohibitively high risk for
surgical aortic valve replacement (SAVR) and
TAVR, although associated with higher proce-
dural risk, would be the only treatment option.
This case report illustrates a patient with a
combination of these complicating features
who underwent successful and uneventful
TAVR after appropriate steps were taken to
predict, prevent, and react to possible
complications.
CASE REPORT
The patient is a 55-year-old male with history
of bicuspid aortic valve who had undergone
SAVR with a 27-mm Freestyle stentless aortic
root bioprosthesis (Medtronic Inc., Min-
neapolis, MN, USA) by modified subcoronary
technique 10 years prior to current presenta-
tion and subsequently three-vessel coronary
artery bypass graft (CABG) 3 years ago. He
presented to an outside hospital with chest
pain and shortness of breath for a few days.
Cardiac enzymes were elevated and he was
found to be in acute decompensated heart
failure and acute renal failure. Trans-thoracic
echocardiogram (TTE) revealed new mild left
ventricular (LV) systolic dysfunction with an
ejection fraction of 40–45%, moderate LV
dilation with LV end diastolic diameter of
65 mm, severe aortic insufficiency with a pres-
sure-half time of 122 ms, and diastolic flow
reversal in the descending and abdominal
aorta. There was also a 20 9 4-mm elongated
highly mobile density associated with the bio-
prosthetic aortic valve (video 1). The systolic
velocity and gradient across the Freestyle root
were also elevated with peak velocity of 3.6 m/s
and mean gradient of 26 mmHg. He also
underwent left heart catheterization. Aor-
togram also showed severe aortic insufficiency.
Left coronary artery (LCA) angiogram showed
the left anterior descending (LAD) has 80%
proximal stenosis and there was competitive
flow into an obtuse marginal (OM) branch. The
left internal mammary artery (LIMA) graft to
the left anterior descending (LAD) and the
saphenous vein graft (SVG) to an OM branch
were patent, but the SVG to the right coronary
artery (RCA) had 90% mid-segment stenosis
and the native RCA had two tandem 75%
mid-segment stenosis (video 2). He was medi-
cally treated and evaluated by a surgeon at the
referring institution but was found to be a poor
surgical candidate for third-time sternotomy
for redo CABG and AVR and was referred to our
institution for a second opinion. He provided
informed consent to receive treatment at our
institution. He was admitted to the intensive
care unit and was medically treated for severe
aortic insufficiency with nitroglycerin infusion
and was empirically treated with broad-spec-
trum antibiotics for possible endocarditis. His
STS risk score was calculated as 16.6% for
operative mortality. His case was discussed at
our weekly valve meeting and two surgeons
concurred that open CABG and AVR would be
extremely high risk; additionally, the surgeons
were concerned about severe adhesions com-
monly present between a stentless valve and
the native aortic root which requires total
aortic root replacement in over 60% of these
patients and adds to the complexity of the
surgery [2]. His blood cultures remained nega-
tive, antibiotics were discontinued, and the
mobile density on the bioprosthesis was
thought to be either a healed vegetation or
degenerative valve leaflet prolapse. There was a
lot of trepidation to offer TAVR, mainly
because of the presence of the highly mobile
density associated with the bioprosthetic valve
and the risk of its embolization; nonetheless,
because he was critically ill and TAVR seemed
to be the only bailout and given his relative
young age, the decision was made to complete
TAVR work-up. Computed tomography
angiography (CTA) was performed and the
images were analyzed with the 3mensio soft-
ware (3mensio Medical Imaging BV, Bilthoven,
The Netherlands). The CTA showed low coro-
nary ostia height with right coronary height of
6.7 mm and left coronary height of 7.9 mm
(Fig. 1a). The aortic sinuses of Valsalva were
relatively small: left coronary sinus = 25 mm,
right coronary sinus = 23 mm, and non-coro-
nary sinus = 24 mm (Fig. 1b). This was partially
due to the subcoronary technique used to
implant the freestyle root, which entails
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trimming of the sinuses. The Coplanar view
was not well visualized on the CT scan because
of severe aortic insufficiency and poor visual-
ization of the aortic sinuses. The bioprosthesis
and the aortic valve annulus were minimally
calcified. The aortic annular area was measured
as 405 mm2 and the perimeter-derived annulus
diameter was calculated as 22.7 mm. The lower
extremity vessel diameters were large enough
to allow a transfemoral approach. The complex
nature of TAVR and the risk of embolization,
stroke, and coronary occlusion were discussed
with the patient and his family, but since the
alternative was medical treatment and hospice,
he decided to proceed with TAVR. We decided
to perform TAVR with the Edwards SAPIEN 3
valve (Edwards Lifesciences Inc., Irvine, CA,
USA). The CoreValve (Medtronic, Minneapolis,
MN, USA) requires greater manipulation during
deployment and in our opinion would be more
likely to cause embolization of the aortic valve
mass; additionally, the sinuses of Valsalva were
too small for a CoreValve. Pre-procedural CT
measured the aortic valve annular area to be
405 mm2, which corresponds to a 23-mm
SAPIEN 3; however, a 27-mm freestyle root has
a internal diameter of 25 mm and based on the
valve-in-valve mobile application a 29-mm
SAPIEN 3 valve was recommended. In val-
ve-in-valve TAVRs, when the type and size of
the degenerative bioprosthetic surgical valve
are known, we size the TAVR valve based on
the known inner diameter of the bioprosthetic
valve and not CT scan or trans-esophageal
echocardiography (TEE) measurements since
non-invasive measurements can be inaccurate
in this setting [3]. We are particularly con-
cerned about undersizing in stentless val-
ve-in-valve TAVR because there is not a stent
scaffold to anchor the valve and undersizing
imposes additional risk for valve embolization.
The other challenge facing us was low coronary
ostia height, which, in combination with small
sinuses of Valsalva, increased the risk of coro-
nary obstruction. Additionally, the presence of
the elongated 20-mm mobile mass on the right
coronary cusp posed additional risk for RCA
occlusion. Although prior studies have shown
that self-expandable valves are associated with
lower risk of coronary occlusion [4], as dis-
cussed earlier, we chose the Edwards SAPIEN 3
valve because of concern over potential
embolization of the mass and also due to the
small size of the sinuses. Despite previous
CABG and bypass of the distal left anterior
descending artery and an obtuse marginal
branch, we still felt that occlusion of the left
coronary system would be a catastrophic event,
and although the RCA was bypassed distally,
both the native RCA and the graft to the RCA
had significant disease and occlusion of the
RCA could also cause significant ischemia.
Therefore, we decided to protect both coro-
naries. A JL4 guide catheter was used to engage
the left main and a JR guide catheter was used
to engage the RCA. Both vessels were wired
Fig. 1 CT angiogram. CTA shows low origin of the right and left coronary arteries with LCA ostium height of 7.9 mm,
and RCA ostium height of 6.7 mm (a). The aortic sinuses of Valsalva are also relatively small (b)
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with 0.01400 prowater. A 3.5 9 8-mm Xience
stent (Abbott Vascular, Santa Clara, CA, USA)
was positioned into the left circumflex artery
and a 2.5 mm 9 23-mm stent was positioned in
the mid RCA, ready to be retracted and
deployed in case of coronary occlusion. Both
guide catheters were then pulled back prior to
valve deployment. As shown in the root
angiogram prior to the valve deployment
(video 3A), another technical challenge was
poor visualization of the aortic sinuses due to
severe aortic insufficiency and lack of landmark
for accurate valve positioning since the Free-
style root does not possess a radiopaque ring
marker or visible posts. We used the position of
the pigtail in the aortic sinus as a crude marker
for the base of the aortic sinuses and guidewires
in the right and left coronary artery served as
landwards to position the top of the SAPEIN 3
valve below this level to avoid coronary
occlusion. After the 29-mm SAPIEN 3 valve was
positioned at the desired location, rapid ven-
tricular pacing was performed and the valve
was deployed without immediate complication
(video 3B). Subsequently, left (video 3C) and
right (video 3D) coronary angiograms showed
that the coronary ostia were not covered. The
left coronary artery wire and undeployed stent
were removed. The mid RCA stenosis was
treated with a 2.5 9 23-mm Xience stent and a
3.0 9 15-mm Xience stent was slightly over-
lapped with the first stent to cover the more
proximal RCA stenosis. Post-dilation was per-
formed with a 3 9 20-mm NC TrekTM balloon
(Abbott Vascular, Santa Clara, CA, USA) with
resolution of the mid RCA stenosis (video 3E).
Final root angiogram showed no evidence of
aortic insufficiency (video 3F). Intra-operative
TEE showed good valve position with no
para-valvular leak (video 4) with peak velocity
of 2.1 m/s and mean gradient of 6 mmHg
across the TAVR valve. The aortic regurgitation
index increased from 0.15 prior to TAVR to
0.47 post-TAVR. He tolerated the surgery well
and was discharged 6 days later with no
peri-operative complication or embolic event.
He was subsequently seen in follow-up at
1 month and the TAVR valve was functioning
normally. He has since been following up with
his local cardiologist.
DISCUSSION
Valve-in-valve TAVR for high-risk patients with
bioprosthetic aortic valve degeneration is a
niche application of TAVR. This case report
illustrates TAVR in an inoperable patient with
significant bioprosthetic aortic valve insuffi-
ciency in the presence of several technically
challenging aspects and high-risk features
including low coronary ostia height, poor visu-
alization of the aortic sinuses, and the coplanar
view due to severe aortic insufficiency, and a
highly mobile aortic valve mass. The main risk
in our patient was the risk of coronary occlusion
given the low coronary ostia height, small
sinuses, and bulky aortic valve mass. Previously
reported risk factors for coronary obstruction
during TAVR include valve-in-valve procedure
especially in bioprostheses with internal stent
frame or as in our case with no stent frame, low
coronary ostia height, high leaflet profile with
bulky leaflet calcification especially at the tips,
and narrow sinuses of Valsalva [5, 6]. Aortogram
during balloon inflation can be used as a strat-
egy to assess the potential for coronary occlu-
sion prior to TAVR [5], but in our case because
of the presence of a large mobile AV mass and
risk of its embolization, we decided not to uti-
lize this technique in order to minimize the
number of balloon inflations across the aortic
valve. Wiring the coronaries and delivering
stents prior to valve deployment is a safe bailout
strategy, and if coronary occlusion occurs, the
stent can be readily pulled back and deployed
[7]. Additionally, in our case the wires in the
coronaries served as landmarks to deploy the
valve below their level and avoid coronary
occlusion. The other risky feature of our case
was the risk of embolization of the aortic valve
mass. TAVR has been rarely attempted in the
presence of a mobile aortic valve mass. Our lit-
erature search in PubMed for TAVR in the set-
ting of mobile aortic valve mass yielded only
one case report in which a 78-year-old man
underwent TAVR with the CoreValve system in
the presence of a 1 9 0.4-cm mobile aortic valve
mass. He suffered immediate peri-procedural
stroke and the embolized valve tissue was
extracted with endovascular technique [8].
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Although none of the embolic protection devi-
ces are currently FDA-approved, and we did not
have experience in using these devices, their
usage should be considered in experienced
centers in the presence of mobile aortic valve
mass, and we found a case report in which the
Claret CE ProTM (Claret Medical, Inc. Santa
Rosa, CA, USA) embolic protection device was
utilized in Europe in a patient with a mobile
mass at the tip of the aortic valve leaflet and
TAVR was performed without peri-procedural
stroke [9].
CONCLUSIONS
High-risk anatomical features should not dis-
suade experienced operators from offering
TAVR to inoperable patients in whom TAVR is
the only viable option and the alternative is
medical therapy, which carries a dire prognosis
in severe AV disease; nevertheless, the patient
needs to have a clear understanding of the
increased risk of the procedure. TAVR can still
be carried out in these patients if there is
meticulous procedural planning, potential
complications are anticipated, and appropriate
preparations are made to avoid them or to deal
with them if they occur.
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